Overview
Retham Technologies™ LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputat...See more
Website
https://www.rethamtechnologies.com/Industry
Biotechnology Research
Company size
4 employees
Headquarters
Milwaukee
Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
$1.5M • Seed
Announced on 9/15/2026
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.